CAPR · Categories · Downgrades
CAPR - Analyst downgrades
Capricor Therapeutics Inc. (CAPR) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for CAPR
- Capricor Therapeutics downgraded by Maxim GroupMaxim Group downgraded Capricor Therapeutics from Buy to Hold
- Capricor Therapeutics downgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald downgraded Capricor Therapeutics from Overweight to Neutral and set a new price target of $3.50
- Capricor Therapeutics downgraded by OppenheimerOppenheimer downgraded Capricor Therapeutics from Outperform to Perform
- Capricor Therapeutics downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Capricor Therapeutics from Overweight to Neutral and set a new price target of $2.00
- Capricor Therapeutics downgraded by H.C. WainwrightH.C. Wainwright downgraded Capricor Therapeutics from Buy to Neutral
- Capricor Therapeutics downgraded by Ladenburg ThalmannLadenburg Thalmann downgraded Capricor Therapeutics from Buy to Neutral
- Capricor Therapeutics downgraded by Alliance Global Partners with a new price targetAlliance Global Partners downgraded Capricor Therapeutics from Buy to Neutral and set a new price target of $7.00
- Capricor Therapeutics downgraded by Roth Capital with a new price targetRoth Capital downgraded Capricor Therapeutics from Buy to Neutral and set a new price target of $7.00
- Capricor Therapeutics downgraded by B. Riley Securities with a new price targetB. Riley Securities downgraded Capricor Therapeutics from Buy to Neutral and set a new price target of $10.00